BDSX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Biodesix Inc · Healthcare · Diagnostics & Research

Open interactive chart View report data
Latest close 21.20 USD
-3.6% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 40.5% above the Trend Line and sits at 81.1% of its 52-week range. The latest completed week returned -3.6%, after a -3.6% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 56/100. Near-term considerations: volume confirmation is below normal; earnings are due in 3d.

Setup score 62 out of 100
Latest Close 21.20 USD 31 Jul 2026
1W Return -3.6% latest completed week
4W Return -3.6% short-term follow-through
12W Return 38.4% quarterly tape
Trend Breadth 67.3% 35 of 52 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • The trend backdrop is active with a 28-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
  • Activity pressure is constructive, supporting the smart-money activity read.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -3.6% Latest completed week; four-week move -3.6%. Indicator stack 82/80 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 56/100 45 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 40.5% above the Trend Line and sits at 81.1% of its 52-week range. The latest completed week returned -3.6%, after a -3.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.9312-week average 0.77

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.93Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -3.6% over four weeks, 38.4% over 12 weeks, and 191.9% over one year. The current trend has remained active for 28 consecutive weeks.

Performance by holding period

1W-3.6%
4W-3.6%
12W38.4%
26W108.5%
52W191.9%
Active trend streak28 weeks
Active weeks in one year35
Trend breadth67.3%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.00Latest activity-pressure read.
Pressure change147.3%Four-week change in activity pressure.
Leadership65.93Latest relative-leadership reading.
RS change-16.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 79% Model confidence 76%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength25/100Blend of value, momentum, and quality. Underlying universe rank 76; rank 1 is best.
Value23/100Relative valuation strength. Underlying universe rank 78; rank 1 is best.
Quality10/100Profitability and accounting quality. Underlying universe rank 91; rank 1 is best.
Momentum97/100Medium-term price momentum. Underlying universe rank 4; rank 1 is best.
Growth82/100Revenue and earnings growth. Underlying universe rank 19; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
2.4x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-8.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
82.1%
Gross profit retained from each unit of revenue.
Operating margin
-24.9%
Operating profit retained from revenue.
Free-cash-flow margin
-25.4%
Free cash flow generated from revenue.
Return on invested capital
-32.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
29.1%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-10.8%
Net share repurchases relative to market value.
Shareholder yield
-10.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-2.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity1 / 1

1 acquisitions and 1 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment56/100

Weighted news tone is neutral across 45 relevant articles.

17 positive · 25 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-14.9%Distance below the 52-week high.
13-week volatility15.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+38.8%Week of 26 Jun.
Worst week-19.0%Week of 24 Apr.
Latest week-3.6%Week of 31 Jul.

Shape of recent returns

Strong gains12
Modest gains2
Flat weeks0
Modest losses3
Sharp losses9
Recent vol15.2%13-week weekly-return volatility.
Base vol15.1%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew13.6% / -8.3%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape63/100

Trend, activity pressure, participation, and risk combine to a 63/100 tape read.

 Indicator analysis80/100

Latest 12-week confirmation: trend 12/12, activity pressure 6/12, relative leadership 12/12.

Activity pressure 0.93; No reversal markers Factors35/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 87; Small Cap Core rank 84 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment56/100

Weighted news tone is neutral across 45 relevant articles.

Biodesix Inc (BDSX) Technical Analysis: Support, Resistance, Indicators & Moving Averages Insiders1 / 1

1 acquisitions and 1 disposals in the latest 180-day insider tape.

 Earnings3d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202621.20 USD-3.6%15.09 USD21.26 USD1.0065.93272.8KOn
24 Jul 202622.00 USD9.0%14.60 USD21.33 USD1.0276.36340.6KOn
17 Jul 202620.19 USD-5.7%14.09 USD21.33 USD1.0062.06268.8KOn
10 Jul 202621.42 USD-2.6%13.64 USD21.35 USD0.7667.96422.4KOn
3 Jul 202621.99 USD-5.8%13.19 USD21.35 USD0.4079.15467.2KOn
26 Jun 202623.34 USD38.8%12.71 USD21.36 USD0.0896.40652.5KOn
19 Jun 202616.81 USD11.6%12.21 USD21.37 USD-0.1938.88374.4KOn
12 Jun 202615.06 USD-2.6%11.88 USD21.42 USD-0.2429.68224.6KOn
5 Jun 202615.46 USD-5.3%11.64 USD21.52 USD-0.2037.84182.2KOn
29 May 202616.32 USD9.3%11.38 USD21.59 USD-0.1440.74300.3KOn
22 May 202614.93 USD5.4%11.07 USD21.66 USD-0.2834.19128.3KOn
15 May 202614.17 USD-7.5%10.79 USD21.74 USD-0.3630.08280.6KOn
8 May 202615.32 USD38.3%10.53 USD21.80 USD-0.2441.67826.5KOn
1 May 202611.08 USD4.1%10.27 USD21.89 USD-0.148.96243.4KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.